Previous Article | Next Article 
Journal of Clinical Microbiology, May 2000, p. 1804-1806, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Distribution of Rotavirus VP4 Genotypes and VP7 Serotypes among
Nonhospitalized and Hospitalized Patients with Gastroenteritis and
Patients with Nosocomially Acquired Gastroenteritis in
Austria
M.
Frühwirth,1,*
S.
Brösl,2
H.
Ellemunter,1
I.
Moll-Schüler,3
A.
Rohwedder,4 and
I.
Mutz2
Department of Pediatrics, University
Hospital, Innsbruck,1 Children's
Hospital, Leoben,2 and
Wyeth-Lederle, Vienna,3 Austria, and
Institute for Microbiology and Virology, Bochum,
Germany4
Received 23 August 1999/Returned for modification 8 December
1999/Accepted 21 February 2000
 |
ABSTRACT |
To assess the potential benefits of a reassortant tetravalent
rotavirus vaccine, we investigated stool specimens from children in
three different groups by reverse transcription-PCR (RT-PCR) for
rotavirus G and P types: (i) children not hospitalized with community-acquired rotavirus-acute gastroenteritis (RV-AGE), (ii) children hospitalized for RV-AGE, and (iii) children with nosocomially acquired RV-AGE. From a total of 553 samples investigated, 335 were
positive by enzyme-linked immunosorbent assay, of which 294 (88%)
were positive by RT-PCR. Among the RT-PCR-positive samples, the predominant types were G1P[8] (84%), followed by G4P[8] (9%) and G3P[8] (2%). No differences between the three groups were observed, suggesting that community vaccination will diminish the
most cost-relevant cases of hospitalizations and nosocomial infections.
 |
INTRODUCTION |
Rotavirus (RV) is responsible for
6% of deaths among children under 5 years of age and for 25% of
deaths due to diarrheal disease in developing countries (6,
15). Immunization against RV with a potent vaccine (the licensed
RV vaccine had to be withdrawn because of its possible association with
intussusception [5]) will have a dramatically
beneficial effect. In developed countries, where RV-acute
gastroenteritis (RV-AGE) is usually mild (4, 13, 16, 26) but
causes enormous socioeconomic costs (2, 13, 23), assessment
of the need for a RV vaccine will require national estimates of the
burden of disease. Therefore, we performed a prospective study on RV
disease which provides information about the incidence of the disease,
hospitalizations, and nosocomial infections in Austria. A child's risk
of contracting a community-acquired case of RV-AGE was 1.3 per 100 children-years and that of contracting a nosocomial infection was 2.59 per 1,000 hospital-days. These data will be central for considerations
in introducing a vaccine in Austria. In addition to epidemiologic
information, data on the diversity of RV in Austria need to be
collected, since the reassortant vaccine is based on serotype-specific
protection against the four most common serotypes of RV prevalent
worldwide. RV is composed of two double-capsid layers that surround the
virus core, which contains 11 segments of double-stranded (ds) RNA. The
two outer capsid proteins of the virus, VP7 (encoded by gene segment 9)
and VP4 (encoded by gene segment 4), are capable of inducing production
of neutralizing antibodies (7). The major neutralizing antigen, VP7, is a glycoprotein and carries the G-serotype specificity, while the minor neutralizing antigen, VP4, carries the P-serotype specificity. Since serotypic specificity is defined and characterized by serological methods, the terms G type and P type (genotype) are used
for typing of RV by molecular biological methods. To date, at least 14 G types and 18 P types have been identified in humans and animals. G
serotypes 1 to 4 are the most prevalent in humans, with between 71 and
97% of the strains characterized (8). Eight P genotypes
have been found in humans, although the majority of strains belong to
only two P genogroups (genogroups P[4] and P[8]) (8).
European data on RV P types are available only for Italy, but data from
Germany and Switzerland will soon be available. In view of the
possibility of genetic shift and drift, it is essential to determine
the P and G types of RV, both before and after mass immunization, for
detection of vaccine failure. As yet, there are no national data about
serotype distribution in Austria. In order to fill this gap in
information, we investigated in a prospective study 335 stool samples
by reverse transcription-PCR (RT-PCR) to assess the potential benefit
of a reassortant tetravalent RV vaccine for Austria and to evaluate
differences between community-acquired nonhospitalized, hospitalized,
and nosocomial cases.
 |
MATERIALS AND METHODS |
Accurate diagnosis of an RV-AGE was made by investigating stool
specimens by enzyme-linked immunosorbent assay (ELISA) (TestPack; Abbott, Delkenheim, Germany) as part of a prospective study to evaluate
the RV disease burden in Austria. The study was performed in Innsbruck
and Leoben between December 1997 and May 1998 and included children
between 0 and 48 months of age with diarrhea who consulted a
pediatrician participating in this study or who were hospitalized
either at the University Hospital of Innsbruck or at the Children's
Hospital of Leoben. Furthermore, all nosocomial cases which occurred in
one of these hospitals were documented and stool specimens were
collected. Written informed consent was obtained from the parents of
the subjects before investigation. All ELISA-positive as well as some
ELISA-negative stool specimens were further investigated by RT-PCR at
the Institute for Microbiology and Virology, University of Bochum,
Bochum, Germany. Briefly, double-stranded RNA extracted from stool
specimens was isolated by phenol-chloroform extraction and was
subsequently purified with an RNAid PLUS KIT (Dianova, Hamburg,
Germany) according to the instructions of the manufacturers. The
purified RNA was used as a template for G and P typing by RT-PCR. G and
P typing was done by the RT-nested PCR method as described by Gentsch
et al. (9) and Gouvea et al. (14). The primers
and conditions were the same as described by them.
 |
RESULTS |
General.
A total of 553 specimens were collected during the
study period from children with AGE; 335 samples were positive for RV
group A antigen by ELISA (Table 1).
Further analyses of the ELISA-positive samples by RT-PCR detected the G
and P types in 294 of 335 samples (88%), whereas 41 (12%) were
negative for both the G and P types. Overall, strains of G type 1 in
combination with P type 8 (G1P[8]) were the most prevalent (84%),
followed by strains of G4P[8]) (9%) and G3P[8]) (2%) In two
samples the G type could be determined but the P genotypes could not,
and in two further samples, the P genotypes could be determined but
their G types could not.
Mixed infections.
Mixed infections were detected in nine
(2.7%) samples. All of them had strains of more than one G type, and
only one had more than one P type. Six of nine possessed strains of
genotypes G1P[8] and G4P[8], and two possessed strains of genotypes
G1P[8] and G3P[8]. Strains with dual P genotypes, P[8] and
P[9], were detected in only one sample in combination with strains of
G types G1 and G2. All mixed infections identified were confirmed by
using the genotype-specific primers in the second amplification and
typing reactions both as single primers and as a primer mixture.
Serotypes in patient subpopulations.
The distribution of the
serotypes in the different groups of patients (those with
community-acquired not hospitalized, hospitalized, and nosocomial cases
of RV-AGE) is shown in detail in Table 2. There was almost no difference between the three groups in the G- and
P-type distributions of their strains.
ELISA-positive and RT-PCR-negative samples.
Forty-one (12%)
of the RV antigen-positive samples were absolutely negative by RT-PCR.
With the exception of two samples in which rotavirus RNA could be
detected, all other RT-PCR-negative samples were also negative by gel
electrophoresis. For these two samples, typing was not possible because
we were not able to obtain a first-round PCR product which would allow
typing by sequencing.
Retesting of ELISA-negative samples by RT-PCR.
Twenty-three of
the total of 218 (10.5%) RV antigen-negative specimens were analyzed
for G and P types by RT-PCR. Of these, the negative result of the RV
antigen test was confirmed for 18 samples. G- and P-type-specific
amplification products were detected in five (21.7%) samples. A type
G1P[8] strain was observed in three samples, a type G4P[8] strain
was observed in one sample, and one sample possessed type G1 and G4
strains. The P type could not be determined for the strain in this sample.
 |
DISCUSSION |
Introduction of a reassortant tetravalent RV is under
consideration in Austria. In this context, information about the
prevalence of RV disease and on the serotype diversity of RV is of
great relevance. Therefore, we investigated the G- and P-serotype
distributions of RV strains that cause disease in this country.
Molecular epidemiological methods for P genotyping were first developed
in the beginning of the 1990s (9, 14), and the majority of
epidemiological studies describe only the distributions of G types. To
our knowledge, P-typing data are currently available only for Italy
(1). The results of G typing in our study are comparable to
those of studies performed in other European countries and the United
States (3, 10, 18). The most prevalent strains showed G1 and
G4 specificity. Gerna et al. (11) reported that 84% of all
strains investigated between 1981 to 1988 were of type G1 and G4.
Gentsch et al. (8) reviewed the prevalence of G serotypes
and found that 71 to 97% of the strains characterized belonged to
these serotypes. The high percentage (93%) of G1 and G4 serotypes
among isolates found in Austria is closely similar to that in Australia
(24, 25, 27), Israel (22), and The Netherlands.
Since the data of the present study are the first such data for
Austria, it is not possible to provide information on the year-to-year
variability in the distribution of RV serotypes in this country.
Further investigations will have to be done after introduction of a
vaccine for early detection of vaccine failures due to such causes as
genetic changes. The value of P genotyping is not yet clearly
established. The combined genotyping may have advantage in identifying
unusual viruses. Furthermore, it may help in clarifying the
importance of VP4 in inducing protective immunity. Unusual G-type
and/or P-type combinations, such as those found in Italy and Australia with G6P[13] specificities (12, 19) or like those in
other countries (e.g., G1P[6] and G9P[6]) (21, 22), were
not detected. Recently Gentsch et al. (8) and Parashar et
al. (20) published data from a "global collection" which
includes specimens from the United States, Costa Rica, Korea, Israel,
China, Mexico, Bolivia, India, and Bangladesh. These data have shown
that the common strain G1P[8] was predominant (53%), followed by
G4P[8] (14.3%), G2P[4] (10.7%), G3P[8] (5.4%), strains of
mixed genotypes (2.6%), and other genotypes (18.4%). The relatively
low frequency of other genotypes or combinations in our study
population indicates that the genetic diversity of the Austrian
population of strains is smaller than that reported for the global collection.
The subtypes of RV strains that are responsible for community-acquired
AGE not requiring hospitalization of the patient or RV strains that
cause severe AGE necessitating hospitalization as well as RV strains
that cause nosocomial cases of AGE had nearly identical distribution
patterns. Therefore, we hypothesize that vaccination of the community
will decrease the frequency of the most cost-relevant cases of
gastroenteritis, namely, the hospitalized and nosocomial ones. In the
face of exploding costs of health care provision, information about the
cost-effectiveness of a medical procedure such as vaccination is very
relevant in national health decision making. Furthermore, our study
enabled a comparison between the results of ELISA and PCR. We
found that the ELISA was false positive for 12% of the samples
compared to the results of RT-PCR. Similar rates of false-positive
results for samples tested by the TestPack ELISA were described by
Lipson et al. (17).
We believe that the description of RV subtype diversity in different
groups of children with RV-AGE in Austria is predictive for use in
policy decision making and that vaccination with a reassortant
tetravalent vaccine would protect the Austrian population from
infection with RV.
 |
ACKNOWLEDGMENT |
We thank Rajam Csordas-Iyer for critically reading the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pediatrics, Innsbruck, University Hospital, Anichstrasse 35, A-6020
Innsbruck, Austria. Phone: 43-512-504-3501. Fax: 43-512-504-3484. E-mail: Martin.Fruehwirth{at}uibk.ac.at.
 |
REFERENCES |
| 1.
|
Arista, S.,
E. Vizzi,
D. Ferraro,
A. Cascio, and R. Di Stefano.
1997.
Distribution of VP7 serotypes and VP4 genotypes among rotavirus strains recovered from Italian children with diarrhea.
Arch. Virol.
142:2065-2071[CrossRef][Medline].
|
| 2.
|
Avendano, P.,
D. O. Matson,
J. Long,
A. Whitney,
C. C. Matson, and L. K. Pickering.
1993.
Cost associated with office visits for diarrhea in infants and toddlers.
Pediatr. Infect. Dis.
12:897-902.
|
| 3.
|
Bears, G.,
U. Desselberger, and T. Fewlett.
1989.
Temporal and geographical distribution of human rotavirus serotypes, 1983 to 1988.
J. Clin. Microbiol.
27:2827-2833[Abstract/Free Full Text].
|
| 4.
|
Berner, R.,
R. F. Schumacher,
S. Hameister, and J. Forster.
1999.
Occurrence and impact of community-acquired and nosocomial rotavirus infections a hospital-based study over 10 y.
Acta Paediatr. Suppl.
426:48-52.
|
| 5.
|
Centers for Disease Control and Prevention.
1999.
Intussusception among recipients of rotavirus vaccine-United States, 1998-1999.
JAMA
282:520-521[Free Full Text].
|
| 6.
|
De Zoysa, I., and R. G. Feacham.
1985.
Interventions for the control of diarrheal disease among young children: rotavirus and cholera immunization.
Bull W. H. O.
63:569-583[Medline].
|
| 7.
|
Estes, M. K.
1996.
Rotaviruses and their replication, p. 1625-1655.
In
B. M. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 8.
|
Gentsch, J. R.,
P. A. Woods,
M. Ramachandran,
B. K. Das,
J. P. Leite,
A. Alfieri,
R. Kumar,
M. K. Bhan, and R. I. Glass.
1996.
Review of G and P typing studies from a global collection of rotavirus strains: implications for vaccine development.
J. Infect. Dis.
174:30-36.
|
| 9.
|
Gentsch, J. R.,
R. I. Glass,
P. Woods,
V. Gouvea,
M. Gorziglia,
J. Flore,
B. K. Das, and M. K. Bhan.
1992.
Identification of group A rotavirus gene 4 types by polymerase chain reaction.
J. Clin. Microbiol.
30:1365-1373[Abstract/Free Full Text].
|
| 10.
|
Gerna, G.,
S. Arista,
N. Passarani,
A. Sarasani, and M. Battaglia.
1987.
Electropherotype heterogeneity within serotypes of human rotavirus strains circulating in Italy.
Arch. Virol.
95:129-135[CrossRef][Medline].
|
| 11.
|
Gerna, G.,
A. Sarasani,
S. Arista,
A. di Matteo,
L. Giovannelli,
M. Parea, and P. Halonen.
1990.
Prevalence of human rotavirus serotypes in some European countries 1981-1988.
Scand. J Infect. Dis.
22:5-10[Medline].
|
| 12.
|
Gerna, G.,
A. Sarasani,
M. Parea,
S. Arista,
P. Miranda,
H. Brüssow,
Y. Hishono, and J. Flores.
1992.
Isolation and characterization of two distinct human rotavirus strains with G6 specificity.
J. Clin. Microbiol.
30:9-16[Abstract/Free Full Text].
|
| 13.
|
Glass, R. I.,
P. E. Kilgore,
R. C. Holman,
S. Jin,
J. C. Smith,
P. A. Woods,
M. J. Clarke,
M. S. Ho, and J. R. Gentsch.
1996.
The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden.
J. Infect. Dis.
174:5-11.
|
| 14.
|
Gouvea, V.,
R. J. Glass,
P. Woods,
K. Taniguchi,
H. F. Clark, and Z. Y. Fang.
1990.
Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens.
J. Clin. Microbiol.
28:276-282[Abstract/Free Full Text].
|
| 15.
|
Institute of Medicine.
1986.
The prospects of immunizing against rotavirus, p. D13-1-12.
In
New vaccine development: diseases of importance in developing countries, vol. 2. National Academy Press, Washington, D.C.
|
| 16.
|
Johansen, K.,
R. Bennet,
K. Bondesson,
M. Eriksson,
K. O. Hedlund,
K. De Verdier Klingenberg,
I. Uhnoo, and L. Svensson.
1999.
Incidence and estimates of disease burden of rotavirus in Sweden.
Acta Paediatr. Suppl.
426:20-23.
|
| 17.
|
Lipson, S. M.,
G. P. Leonardi,
R. J. Salo,
T. E. Schutzbank, and M. H. Kaplan.
1990.
Occurrence of nonspecific reactions among stool specimens tested by the Abbott TestPack rotavirus enzyme immunoassay.
J. Clin. Microbiol.
28:1132-1134[Abstract/Free Full Text].
|
| 18.
|
Matson, D. O.,
M. K. Estes,
J. W. Burns,
H. B. Greenberg,
K. Taniguchi, and S. Urasawa.
1990.
Serotype variation of human group A rotavirus in two regions of the USA.
J. Infect. Dis.
162:605-614[Medline].
|
| 19.
|
Palombo, E. A., and R. F. Bishop.
1995.
Genetic and antigenic characterization of a serotype G6 human rotavirus isolated in Melbourne, Australia.
J. Med. Virol.
47:348[Medline].
|
| 20.
| Parashar, U. D., J. S. Bresee, J. R. Gentsch, and R. I. Glass. Rotavirus. Emerg. Infect. Dis.
4:561-570.
|
| 21.
|
Ramachandran, M.,
B. K. Das,
A. Vij,
R. Kumar,
S. S. Bhambal,
N. Kesari,
H. Rawat,
L. Bahl,
S. Thakur,
P. A. Woods,
R. I. Glass,
M. Bhan, and J. R. Gentsch.
1996.
Unusual diversity of human rotavirus G and P types in India.
J. Clin. Microbiol.
34:436-439[Abstract].
|
| 22.
|
Silberstein, I.,
L. M. Shulman,
E. Mendelson, and I. Shif.
1995.
Distribution of both rotavirus VP4 genotypes and VP7 serotypes among hospitalized and nonhospitalized Israeli children.
J. Clin. Microbiol.
33:1516-1519[Abstract].
|
| 23.
|
Tucker, A. W.,
A. C. Haddix,
J. S. Bresee,
R. C. Holman,
U. D. Parashar, and R. I. Glass.
1998.
Cost-effectiveness analysis of a rotavirus immunization program for the United States.
JAMA
279:1371-1376[Abstract/Free Full Text].
|
| 24.
|
Unicomb, L.,
B. Coulson, and R. Bishop.
1989.
Experience with an enzyme immunoassay for serotyping human group A rotavirus.
J. Clin. Microbiol.
27:586-588[Abstract/Free Full Text].
|
| 25.
|
Unicomb, L., and R. Bishop.
1989.
Epidemiology of rotavirus strains infecting children throughout Australia during 1986-1987: a study of serotype and RNA electropherotype.
Arch. Virol.
106:23-34[CrossRef][Medline].
|
| 26.
|
Vesikari, T.,
T. Rautanen, and C. G. Von Bonsdorff.
1999.
Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features.
Acta Paediatr. Suppl.
426:24-30.
|
| 27.
|
Woods, P. A.,
J. R. Gentsch,
V. Gouva,
L. Mata,
A. Simhon,
M. Santosham,
Z. S. Bai,
S. Urasawa, and R. I. Glass.
1992.
Distribution of serotypes of human rotavirus in different populations.
J. Clin. Microbiol.
30:781-785[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, May 2000, p. 1804-1806, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fischer, T. K., Eugen-Olsen, J., Pedersen, A. G., Molbak, K., Bottiger, B., Rostgaard, K., Nielsen, N. M.
(2005). Characterization of Rotavirus Strains in a Danish Population: High Frequency of Mixed Infections and Diversity within the VP4 Gene of P[8] Strains. J. Clin. Microbiol.
43: 1099-1104
[Abstract]
[Full Text]